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Abstract
A 16 year old female with hypertrophic cardiomyopathy was treated with alcohol ablation for
NYHA class III symptoms on medical therapy. Three months later, patient underwent
a second alcohol ablation procedure for continued symptoms. Follow-up, for 4 years now,
continues to show resolution of symptoms. (Cardiol J 2007; 14: 301304)
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Introduction
Hypertrophic cardiomyopathy (HCM) is a ge-
netic disease characterized by hypertrophy of the
left ventricle and in a subset of patients, obstruction
of the left ventricular outflow tract (LVOT) [1, 2]. Sig-
nificant outflow tract obstruction is an independent
predictor of poor prognosis in patients with HCM [3].
The incidence of LVOT obstruction has been dem-
onstrated to be present in higher than previously
reported percentage of patients when exercise
stress testing was used to provoke a gradient [4].
In the treatment of obstructive HCM non-pharma-
cologic options include surgery and transcatheter
ethanol septal reduction. Dual chamber pacing has
only a limited role. Patients with obstructive HCM
are candidates for septal reduction therapy if they
are severely symptomatic (New York Heart Asso-
ciation functional class III or IV) or have recurrent
syncope despite pharmacologic therapy.
Case report
A 16 year old female with a family history of
hypertrophic cardiomyopathy presented with symp-
toms of increasing fatigue and NYHA functional
class III. She had a loud systolic ejection murmur
at rest, which increased with Valsalva maneuver.
Echocardiography showed septal hypertrophy with
septal thickness of 27 mm (Fig. 1), systolic anteri-
or motion (SAM) of mitral valve leaflet, resting
LVOT gradient of 70 mm Hg which increased to
100 mm Hg with Valsalva maneuver. She had an ep-
isode consistent with presyncope during physical
Figure 1. Pre-ablation parasternal long axis echocardio-
graph showing thickened septum (A) and narrow left
ventricular outflow tract.
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activity and a family history of ventricular arrhyth-
mias. Patient underwent ICD implantation and was
on medical therapy with beta blockers and calcium
channel blockers. Medications were very poorly
tolerated because of hypotension and fatigue.
Patient was no longer able to attend school. Options
of surgical vs. transcatheter ethanol septal reduc-
tion procedures were discussed with her family and
her. A decision was made to proceed with ethanol
septal ablation. First septal perforator branch of the
LAD was engaged with angioplasty catheter and
slow infusion of ethanol was performed. Immedi-
ate resolution of LVOT gradient was noted. Systo-
lic ejection murmur was no longer present. Patient
was monitored in the intensive care unit, cardiac
troponin peaked at 30 and ECG showed septal Q
waves. The next post-procedure day, physical ex-
amination demonstrated recurrence of systolic
murmur at rest. Echocardiogram confirmed recur-
rence of LVOT gradient and presence of SAM of
mitral valve leaflet. The hope was that recurrence
of gradient was in part due to increased edema of
infracted proximal septal tissue and that with de-
velopment of scar and left ventricular remodeling
there will be improvement in LVOT gradient. Clin-
ically, patient reported symptomatic improvement
in her fatigue and she was able to return to school.
Serial echocardiograms showed development of
small scar in the proximal septum but persistence
of LVOT gradient and SAM. Within three months
patient also had recurrence of symptoms. A deci-
sion was made to repeat the transcatheter ethanol
septal reduction procedure with injection of etha-
nol into the second and third septal perforator
branches of LAD. Immediate results of this proce-
dure were equally rewarding as the first one. There
was immediate resolution of LVOT gradient in the
catheterization laboratory and disappearance of
systolic murmur. This time troponin peaked at 50.
We were disappointed when on the second post-
procedure day the murmur returned with the same
intensity and again LVOT obstruction was demon-
strated by echocardiography. But this time patient
felt significantly better and had objective improve-
ment in physical activity tolerance.  She returned
to school full time and was able to finish high school.
Serial echocardiograms demonstrated gradual thin-
ning of the interventricular septum, disappearance
of LVOT obstruction and SAM by the third month
post second procedure. Septal remodeling with pro-
gressive septal thinning was observed to occur over
period up to 1 year (Fig. 2). Patient was able to attend
college and is now working full time as a paramedic.
She has no limitations of physical activity and is able
to exercise regularly.
Discussion
With surgical myectomy, the proximal septum
is approached through the aortic valve via an aortot-
omy and 3 to 15 g of septal muscle is removed [58].
Perioperative mortality is reported to be less than
1% and centers with extensive experience report
even lower mortality in uncomplicated cases. Com-
plications of myectomy include a ventricular septal
defect due to excessive removal of septal muscle,
ischemia of the hypertrophied muscle due to inad-
equate intraoperative protection and resulting left
ventricular dysfunction, aortic valve regurgitation
due to traction on the aortic valve to improve visu-
alization of and access to the interventricular sep-
tum, and left bundle branch block (LBBB) or com-
plete heart block (CHB) requiring a permanent
pacemaker in approximately 510% of patients.
Reduction of LVOT gradient, improvement in func-
tional class and long-term survival is excellent af-
ter surgical myectomy at experienced centers [9].
Transcatheter ethanol septal ablation consists
of infarction and thinning of the proximal interven-
tricular septum via infusion of ethanol into the first
septal perforating branch of the left anterior de-
scending coronary artery through an angioplasty
catheter.  Ethanol septal ablation reduces LV out-
flow obstruction, improves symptoms, and in-
creases exercise capacity. Long-term benefit re-
sults from the creation of localized septal infarction
and scarring, which increase LV outflow diameter
as a result of septal thinning and therapeutic
remodeling [1013]. This procedure significantly
reduces the resting LVOT gradient, the inducible
gradient and improves functional class [14]. A subset
of patients who do not show initial benefit can have
later improvement [15]. These late responders had
Figure 2. Post-ablation (2nd ablation) parasternal long
axis echocardiography showing septal scar (A) with
resolution of left ventricular outflow tract obstruction.
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a similarly improved LVOT gradient at one year
compared to those who improved immediately af-
ter the procedure. Complete heart block (CHB)
requiring a pacemaker occurs in 1425% of patients
after ethanol septal ablation [16, 17].
Both surgical myectomy and ethanol septal
ablation reduce LV outflow tract obstruction and
improve NYHA class in HCM. When efficacy of the
two techniques was compared the resting LVOT
gradient fell to a similar degree with both ethanol
ablation and surgical myectomy, there was similar
reduction in septal thickness and improvement in
exercise duration in both groups. The incidence of
CHB was higher with ethanol ablation, but surgery
was associated with a significant increase in mild
aortic regurgitation [18]. A recent study showed
consistent anterior basal septal reduction with my-
ectomy but not with alcohol ablation, as assessed
by cardiac magnetic resonance imaging [19].
The advantages of ethanol ablation include
avoidance of cardiopulmonary bypass, shorter hos-
pital stay and recovery time and reduced expense.
Advantages of surgical myectomy include more
immediate and complete relief of resting and pro-
voked obstruction and concomitant mitral regurgi-
tation, lower incidence of CHB requiring pacemak-
er insertion and proven long-term (> 20 years)
efficacy; similar data with ethanol ablation are not
yet available.
In our patient, four year follow up shows satis-
factory results with improved functional capacity,
lack of LVOT gradient and preservation of left ven-
tricular function without development of complete
heart block. However the degree and extent of the
left ventricular septal thinning is concerning to us.
In retrospect, we probably should have shown more
restrain and allowed more time for the remodeling
before the second ablation procedure.
References
1. Wigle ED, Rakowski H, Kimball BP, Williams WG.
Hypertrophic cardiomyopathy: Clinical spectrum and
treatment. Circulation, 1995; 92: 1680.
2. Maron, BJ, McKenna, WJ, Danielson, GK et al.
American College of Cardiology/European Society of
Cardiology clinical expert consensus document on
hypertrophic cardiomyopathy. A report of the Amer-
ican College of Cardiology Foundation Task Force
on Clinical Expert Consensus Documents and the
European Society of Cardiology Committee for Prac-
tice Guidelines. J Am Coll Cardiol, 2003; 42: 1687.
3. Maron MS, Olivotto I, Betocchi S et al. Effect of left
ventricular outflow tract obstruction on clinical out-
come in hypertrophic cardiomyopathy. N Engl J Med,
2003; 348: 295.
4. Maron MS, Olivotto I, Zenovich AG et al. Hyper-
trophic cardiomyopathy is predominantly disease of
left ventricular outflow tract obstruction. Circulation,
2006; 114: 2232.
5. Morrow AG, Reitz BA, Epstein SE et al. Operative
treatment in hypertrophic subaortic stenosis: Tech-
niques, and the results of pre and postoperative as-
sessments in 83 patients. Circulation, 1975; 52: 88.
6. Beahrs MM, Tajik AJ, Seward JB et al. Hypertrophic
obstructive cardiomyopathy: Ten to 21-year follow-up
after partial septal myectomy. Am J Cardiol, 1983;
51: 1160.
7. Schulte HD, Bircks WH, Loesse B et al. Prognosis of
patients with hypertrophic obstructive cardiomyopa-
thy after transaortic myectomy. Late results up to
twenty-five years. J Thorac Cardiovasc Surg, 1993;
106: 709.
8. Ommen SR, Maron BJ, Olivotto I et al. Long-term
effects of surgical septal myectomy on survival in
patients with obstructive hypertrophic cardiomyopa-
thy. J Am Coll Cardiol, 2005; 46: 470.
9. Flores-Ramirez R, Lakkis NM, Middleton KJ et al.
Echocardiographic insights into the mechanisms of
relief of left ventricular outflow tract obstruction af-
ter nonsurgical septal reduction therapy in patients
with hypertrophic obstructive cardiomyopathy. J Am
Coll Cardiol, 2001; 37: 208.
10. Kuhn H, Gietzen FH, Schafers M et al. Changes in
the left ventricular outflow tract after transcoronary
ablation of septal hypertrophy (TASH) for hyper-
trophic obstructive cardiomyopathy as assessed by
transoesophageal echocardiography and by measur-
ing myocardial glucose utilization and perfusion. Eur
Heart J, 1999; 20: 1808.
11. Mazur W, Nagueh SF, Lakkis NM et al. Regression
of left ventricular hypertrophy after nonsurgical sep-
tal reduction therapy for hypertrophic obstructive
cardiomyopathy. Circulation, 2001; 103: 1492.
12. van Dockum WG, Beek AM, ten Cate FJ et al.
Early onset and progression of left ventricular
remodeling after alcohol septal ablation in hyper-
trophic obstructive cardiomyopathy. Circulation,
2005; 111: 2503.
13. Faber L, Seggewiss H, Gleichmann U. Percutaneous
transluminal septal myocardial ablation in hyper-
trophic obstructive cardiomyopathy: Results with re-
spect to intraprocedural myocardial contrast echocar-
diography. Circulation, 1998; 98: 2415.
14. Yoerger DM, Picard MH, Palacios IF et al. Time
course of pressure gradient response after first alco-
hol septal ablation for obstructive hypertrophic car-
diomyopathy. Am J Cardiol, 2006; 97: 1511.
304
Cardiology Journal 2007, Vol. 14, No. 3
www.cardiologyjournal.org
15. Chang SM, Nagueh SF, Spencer WH, 3rd, Lakkis NM.
Complete heart block: determinants and clinical im-
pact in patients with hypertrophic obstructive cardi-
omyopathy undergoing nonsurgical septal reduction
therapy. J Am Coll Cardiol, 2003; 42: 296.
16. Chen AA, Palacios IF, Mela T et al. Acute predictors
of subacute complete heart block after alcohol septal
ablation for obstructive hypertrophic cardiomyopa-
thy. Am J Cardiol, 2006; 97: 264.
17. Nagueh SF, Ommen SR, Lakkis NM et al. Comparison
of ethanol septal reduction therapy with surgical mye-
ctomy for the treatment of hypertrophic obstructive
cardiomyopathy. J Am Coll Cardiol, 2001; 38: 1701.
18. Valeti US, Nishimura RA, Holmes DR et al. Compa-
rison of surgical septal myectomy and alcohol septal
ablation with cardiac magnetic resonance imaging in
patients with hypertrophic obstructive cardiomyopa-
thy. J Am Coll Cardiol, 2007; 49: 350357.
